| Literature DB >> 29572257 |
Rudolf A Werner1,2,3, Lilja B Solnes1, Mehrbod S Javadi1, Alexander Weich3,4, Michael A Gorin1,5, Kenneth J Pienta5, Takahiro Higuchi2,6,7, Andreas K Buck2,3,6, Martin G Pomper1,5, Steven P Rowe1,5, Constantin Lapa8,3.
Abstract
Reliable standards and criteria for somatostatin receptor (SSTR) PET are still lacking. We herein propose a structured reporting system on a 5-point scale for SSTR PET imaging, titled SSTR-RADS version 1.0, which might serve as a standardized assessment for both diagnosis and treatment planning in neuroendocrine tumors. SSTR-RADS could guide the imaging specialist in interpreting SSTR PET scans, facilitate communication with the referring clinician so that appropriate workup for equivocal findings is pursued, and serve as a reliable tool for patient selection for planned peptide receptor radionuclide therapy.Entities:
Keywords: 68Ga-DOTATATE/-TOC; PET; PRRT; RADS; SSTR; neuroendocrine tumor; peptide receptor radionuclide therapy; somatostatin receptor
Mesh：
Substances：
Year: 2018 PMID： 29572257 DOI： 10.2967/jnumed.117.206631
Source DB: PubMed Journal: J Nucl Med ISSN： 0161-5505 Impact factor: 10.057